Self Study 2024 Release II: Treatment Updates in Myelodysplastic Syndrome
MDS is a complex disease process that leads to ineffective hematopoiesis, often rendering patients transfusion-dependent. Treatment selection is determined based on the Revised International Prognostic Scoring System (IPSS-R) classifying patients as lower- or higher-risk MDS. Treatment goals of lower-risk MDS focus on improvement in peripheral blood counts and decreased transfusion requirements while higher-risk MDS focuses on prolonging survival and decreasing the risk of progression to AML. In this module, participants will evaluate current and potential future treatment advances in the management of both lower- and higher-risk MDS.
Course Information
Treatment Updates in Myelodysplastic Syndrome
UAN# 0465-0000-24-108-H01-P
Author: Rebecca Hunt, PharmD, BCOP
Learning Objectives
- Recognize the place in therapy of novel treatment strategies for the management of MDS
- Recall common and serious adverse events associated with novel therapies for the treatment of MDS
- Evaluate the clinical outcomes for novel treatment strategies for the management of MDS
- Devise a treatment plan for a patient with newly diagnosed or relapsed/refractory MDS
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.